CMS
Medicare to cap cost of GLP-1s for weight loss at $50
Clinical takeaway: The cost cap may open GLP-1 access to Medicare beneficiaries previously priced out of weight-loss treatment, with eligibility tied to BMI thresholds and specific cardiometabolic comorbidities.
GLP-1 receptor agonists have transformed obesity care, but inconsistent coverage and high out-of-pocket costs have kept them out of reach for many older adults. Until now, Medicare Part D coverage for weight loss alone has been restricted. The Medicare GLP-1 Bridge, announced by the Centers for Medicare & Medicaid Services, is an 18-month demonstration program offering eligible Part D enrollees a flat $50 monthly out-of-pocket cost for certain GLP-1 medications starting July 1, 2026, through year-end 2027.
Foundayo, injectable and oral Wegovy, and the KwikPen formulation of Zepbound, will be covered when prescribed for weight reduction alongside structured lifestyle modification.
Eligibility is quite broad, but specifically defined. It requires a BMI 35 or higher; BMI 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension on at least two agents, or stage 3a or higher chronic kidney disease; or BMI 27 or higher with prediabetes, prior myocardial infarction or stroke, or symptomatic peripheral artery disease. Patients already on GLP-1 therapy qualify if they met BMI criteria at initiation, even if their current BMI has dropped below threshold.
Patients prescribed these drugs for indications already covered under Part D, such as Wegovy for cardiovascular risk reduction or Zepbound for obstructive sleep apnea, will continue to access them through their Part D plan rather than the bridge.
The bridge operates outside the standard Part D benefit, with Humana serving as the central processor for prior authorization, claims adjudication, and pharmacy payment. CMS plans to release operational guidance on prior authorization and claims processing this spring. Prescribing providers don't need to be enrolled in Medicare.
However, patients who start GLP-1 therapy under the bridge may face renewed cost barriers in 2028, unless the program is extended or folded into a permanent benefit. CMS has signaled that the bridge is partly intended to collect utilization data ahead of a potential broader Part D coverage policy.
"GLP-1s can be life-changing for patients managing obesity and related conditions," said Chris Klomp, director of Medicare and chief counselor at the U.S. Department of Health and Human Services. "This demonstration is designed to make accessing those medications simpler, more predictable, and more consistent across the Medicare program, which means better quality of life for seniors and better value across the health care system."
Source: Centers for Medicare & Medicaid Services. May 6, 2026. Coming soon: CMS to provide $50 monthly access to GLP-1 medications for Medicare beneficiaries